David Lewis
Stock Analyst at Morgan Stanley
(1.72)
# 2,228
Out of 4,667 analysts
281
Total ratings
66.67%
Success rate
9.66%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $107 → $117 | $115.93 | +0.92% | 23 | Oct 17, 2024 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $266.58 | +12.54% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $222.39 | +23.66% | 23 | Oct 11, 2022 | |
| NVRO Nevro | Maintains: Equal-Weight | $55 → $54 | $4.23 | +1,176.60% | 12 | Aug 4, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $75.24 | +20.95% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $50 → $48 | $0.73 | +6,514.30% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $32.63 | +206.47% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $77.20 | -80.57% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $6.20 | +383.87% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $78.04 | -3.90% | 11 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $45 | $20.37 | +120.91% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $84.92 | -29.35% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $83.59 | -1.90% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $187.43 | +129.95% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $84.11 | +83.09% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $12.15 | +229.22% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $69.54 | +94.13% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $385.68 | -27.40% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $541.82 | -47.40% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $11.41 | +66.52% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $73.74 | +27.47% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $85.50 | -7.60% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $109.27 | +64.73% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $153.11 | +22.13% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $17.87 | +151.82% | 5 | Dec 15, 2020 |
Abbott Laboratories
Oct 17, 2024
Maintains: Equal-Weight
Price Target: $107 → $117
Current: $115.93
Upside: +0.92%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $266.58
Upside: +12.54%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $222.39
Upside: +23.66%
Nevro
Aug 4, 2022
Maintains: Equal-Weight
Price Target: $55 → $54
Current: $4.23
Upside: +1,176.60%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $75.24
Upside: +20.95%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $50 → $48
Current: $0.73
Upside: +6,514.30%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $32.63
Upside: +206.47%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $77.20
Upside: -80.57%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $6.20
Upside: +383.87%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $78.04
Upside: -3.90%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $20.37
Upside: +120.91%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $84.92
Upside: -29.35%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $83.59
Upside: -1.90%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $187.43
Upside: +129.95%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $84.11
Upside: +83.09%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $12.15
Upside: +229.22%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $69.54
Upside: +94.13%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $385.68
Upside: -27.40%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $541.82
Upside: -47.40%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $11.41
Upside: +66.52%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $73.74
Upside: +27.47%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $85.50
Upside: -7.60%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $109.27
Upside: +64.73%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $153.11
Upside: +22.13%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $17.87
Upside: +151.82%